Full Text View
Tabular View
No Study Results Posted
Related Studies
Allopurinol, Glucantime, or Allopurinol/Glucantime for Cutaneous Leishmaniasis in Brazil
This study has been completed.
Study NCT00004755   Information provided by Office of Rare Diseases (ORD)
First Received: February 24, 2000   Last Updated: June 23, 2005   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Leishmaniasis
Additional conditions recognized in this trial
Leishmaniasis, Cutaneous
More general conditions related to this trial
Mastigophora Infections
Parasitic Diseases
Protozoan Infections
Sarcomastigophora Infections
Skin Diseases
Skin Diseases, Infectious
Skin Diseases, Parasitic
Interventions listed in this trial
allopurinol
glucantime
Additional drug interventions recognized in this trial
Meglumine antimoniate
More general drug interventions related to this trial
Anti-Infective Agents
Antimetabolites
Antioxidants
Antiparasitic Agents
Antiprotozoal Agents
Antirheumatic Agents
Enzyme Inhibitors
Free Radical Scavengers
Gout Suppressants
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Therapeutic Uses
Sponsors listed in this trial
National Institute of Allergy and Infectious Diseases (NIAID)
Harvard School of Public Health


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services